A. Ago´cs et al. / Tetrahedron: Asymmetry 12 (2001) 469–476
475
2.12. (3S,3aS,4R,5R,6S)-2-(4-Bromophenyl)-3-car-
obtained as white crystals from hexane/ether (845 mg,
28%), and 10b was a yellow syrup (830 mg, 28%,); m/z
641 (M+H+, PSP). 10a: mp 141–142°C, [h]2D3=+13.6 (c
1.75, CH2Cl2); wmax (KBr) 3060, 2922, 1738, 1590, 1492,
boxymethyl-4,5,6-tribenzyloxy-2,3,3a,4,5,6-hexahydro-
cyclopentapyrazole 17a and (3R,3aR,4R,5R,6S)-2-
(4-bromophenyl)-3-carboxymethyl-4,5,6-tribenzyloxy-
2,3,3a,4,5,6-hexahydro-cyclopentapyrazole 17b
1
1068 cm−1. H NMR (500 MHz): l (ppm) 3.4 (3H, s,
OMe), 3.75 (1H, dd, J3a,4=8.4 Hz, J4,5=5.85 Hz, H-4),
3.8 (1H, dt, J3a,3=8.4 Hz, J3a,6=1.1 Hz, H-3a), 3.88
(1H, s, J5,6=2.85 Hz, H-5), 4.4 (1H, dd, H-6), 4.5 (1H,
d, H-3), 4.6–4.9 (6H, m, -OCH2-), 6.9 and 7.6 (4H, 2d,
aromatic), 7.37 (15H, m, benzyl). 13C NMR: l (ppm)
53.1 (C-3a); 59.1 (OMe); 69.2 (C-3); 71.0; 72.0; 72.4
(-CH2-O); 76.4; 91.7 (C-4, C-5, C-6); 112.9 (C-Br, aro-
matic); 115.0; 131.8 (4C, 4-Br-phenyl); 127.6–128.4
(15C, benzyl); 137.3; 137.5 (3C, C-O, benzyl); 144.3
(C-N, 4-Br-phenyl); 151.8 (CꢁN); 171.2 (CꢁO). Anal.
calcd for C35H33BrN2O5: C, 65.52; H, 5.18; N, 4.37.
Found: C, 65.59; H, 5.11; N, 4.34. 10b [h]2D3=+1.5 (c
1.15, CH2Cl2); wmax (KBr) 3062, 2922, 1738, 1590, 1494,
From 15 (520 mg, 0.84 mmol) the corresponding hydra-
zone was synthesised using the methodology for 21 to
give compound 16 as a red syrup (417 mg, 77%); m/z
643 (M+H+, PSP), [h]D23=+9.2 (c 0.85, CH2Cl2). 1H
NMR: l (ppm) 3.7 (3H, s, -OMe) 3.9–5.1 (10H, m,
-OCH2-, H-4, H-5, H-6), 6.1 (1H, d, J2,3=15.2, H-2),
6.9–7.3 (21H, m, H-3, -CHꢁN and aromatic). Cycload-
dition (general method) starting from 16 (417 mg, 0.65
mmol) furnished two yellow syrups: 17a (45 mg, 11%)
and 17b (110 mg, 26%); m/z 641 (M+H+, PSP). 17a:
[h]2D3=+21.6 (c 0.94, CH2Cl2); wmax (KBr) 3064, 2922,
1
1738, 1590, 1454, 1102 cm−1. H NMR (500 MHz): l
(ppm) 3.8 (1H, m, J3a,4=6.7 Hz, J4,5=5.8 Hz, H-4), 3.9
(3H, s, OMe), 4.05 (1H, dd, J5,6=4.6 Hz, H-5), 4.2 (1H,
dd, J3a,3=10.0 Hz, H-3a), 4.35 (1H, d, H-3), 4.4 (1H, d,
H-6), 4.6–4.9 (6H, m, -OCH2-), 7.35 (19H, m, aro-
matic). 13C NMR: l (ppm) 53.0 (C-3a); 60.0 (OMe);
69.4 (C-3); 71.3; 71.6; 72.9 (-CH2-O); 71.8; 78.8; 79.9
(C-4, C-5, C-6); 112.6 (C-Br); 115.0; 131.8 (4C, 4-Br-
phenyl); 127.4-128.5 (15C, benzyl); 137.5 (3C, C-O,
benzyl); 144.5 (C-N, 4-Br-phenyl); 154.5 (CꢁN); 171.3
(CꢁO). Anal. calcd for C35H33BrN2O5: C 65.52; H, 5.18;
N, 4.37. Found: C, 65.39; H, 5.23; N, 4.31%. 17b:
[h]2D3=+53.5 (c 0.95, CH2Cl2); wmax (KBr) 3030, 2922,
1
1076 cm−1; H NMR (500 MHz): l (ppm) 3.75 (3H, s,
-OMe), 3.82 (1H, d, J4,5=6.6 Hz, J4,3a:0 Hz, H-4), 3.9
(1H, dd, J5,6=9.2 Hz, H-5), 4.2 (1H, dd, J3a,3=2.9 Hz,
H-3a), 4.3–4.5 (4H, m, -OCH2-), 4.6 (1H, d, H-3), 4.8
and 5.2 (2H, q, -OCH2-), 5.0 (1H, d, H-6), 6.95 and 7.4
(19H, 2m, aromatic). 13C NMR: l (ppm) 53.0 (C-3a);
58.0 (OMe); 64.2 (C-3); 71.0; 71.9; 72.3 (-CH2-O);
78.0; 89.7 (C-4, C-5, C-6); 112.6 (C-Br); 15.5; 131.7
(4C, 4-Br-phenyl); 127.6–128.5 (15C, benzyl); 137.2
(3C, C-O, benzyl); 145.6 (C-N, 4-Br-phenyl); 158.3
(CꢁN); 172.3 (CꢁO). Anal. calcd for C35H33BrN2O5: C,
65.52; H, 5.18; N, 4.37. Found: C, 65.62; H, 5.21; N,
4.29%.
1
1748, 1574, 1488, 1112 cm−1. H NMR (500 MHz): l
(ppm) 3.45 (1H, dd, J5,6=10.5 Hz, H-5), 3.8 (3H, s,
-OMe), 4.05 (1H, dd, J3a,3=3.2 Hz, H-3a), 4.13 (1H, d,
J
4,5=4.6 Hz, J3a,4=7.5 Hz, H-4), 4.5–5.1 (6H, m,
-OCH2-), 4.65 (1H, d, H-3), 4.70 (1H, d, H-6), 7.3
(19H, m, aromatic). 13C NMR: l (ppm) 52.8 (C-3a);
56.9 (OMe); 64.7 (C-3); 70.9; 71.9; 73.0 (-CH2-O); 68.7;
73.9; 83.7 (C-4, C-5, C-6); 112.6 (C-Br); 115.9; 131.7
(4C, 4-Br-phenyl); 127.3–128.7 (15C, benzyl); 137.7
(3C, C-O, benzyl); 145.9 (C-N, 4-Br-phenyl); 159.1
(CꢁN); 172.0 (CꢁO). Anal. calcd for C35H33BrN2O5: C,
65.52; H, 5.18; N, 4.37. Found: C, 65.64; H, 5.17; N,
4.42%.
2.11. (3aS,4R,5R,6S)-2-(4-Bromophenyl)-4,5,6-tribenzyl-
oxy-2,3,3a,4,5,6-hexahydro-cyclopentapyrazole 14
From 12 (80 mg, 0.55 mmol) the corresponding alde-
hyde and hydrazone were formed using the methodol-
ogy described for 21, to give 13 as a red syrup (69 mg
(81%); m/z 585 (M+H+, PSP), [h]2D3=−10.3 (c 0.9,
1
CH2Cl2). H NMR: l (ppm) 4.2–5.0 (9H, m, -OCH2-,
H-2, H-3, H-4), 5.65 (3H, m, H-5, H-6a,b), 6.55 (1H,
m, H-1) 6.85 and 7.45 (19H, 2m, aromatic). Cycloaddi-
tion starting from hydrazone 13 (69 mg, 0.12 mmol)
according to the general method furnished one
diastereomer, 14, as a yellow syrup (21 mg, 30%); m/z
583 (M+H+, PSP), [h]D23=−12.5 (c 0.6, CH2Cl2); wmax
(KBr) 3030, 2852, 1590, 1492, 1102 cm−1. 1H NMR
2.13. (3aS,4S,5S,6S)-2-(4-Bromophenyl)-4,5,6-tribenzyl-
oxy-2,3,3a,4,5,6-hexahydro-cyclopentapyrazole 21
To a solution of 17 (300 mg, 0.55 mmol) in acetone (20
mL) and water (2 mL) was added cadmium carbonate
(1 g) and mercury(II) chloride (360 mg, 1.33 mmol); the
suspension was then stirred for 24 hours. The suspen-
sion was filtered, evaporated and taken up in
dichloromethane. The organic phase was washed with
sat. NaHCO3 (50 mL) and 10% potassium iodide solu-
tion (50 mL), then dried and evaporated. From this
crude product 225 mg (71%) of the corresponding
4-bromophenylhydrazone 20 was obtained (as
described for 5) as a red syrup. Compound 20: m/z 585
(500 MHz): l (ppm) 3.15 (1H, dd, J3,3%=9.3 Hz, J3,3a
=
11.7 Hz, H-3), 3.7 (1H, t, H-4), 3.95 (1H, m, J3a,4=6.2
Hz, J3%,3a=11.1 Hz, H-3a), 4.05 (1H, t, H-3%), 4.15 (1H,
t, J4,5=5.2 Hz, H-5), 4.4 (1H, d, J5,6=4.8 Hz, H-6), 4.7
(6H, m, -OCH2-), 6.8–7.4 (19H, m, aromatic). 13C
NMR: l (ppm) 53.0 (C-3a); 54.9 (C-3); 71.8; 72.0
(-CH2-O); 77.7; 81.2; 84.9 (C-4, C-5, C-6); 111.5 (C-Br,
aromatic); 114.7 and 131.7 (4C, p-Br-phenyl); 127.7–
128.5 (15C, benzyl); 137.3–137.6 (3C, C-O, benzyl),
146.0 (C-N, p-Br-phenyl); 159.3 (CꢁN). Anal. calcd for
C29H33BrN2O3: C, 67.93; H, 5.35; N, 4.80. Found: C,
67.80; H, 5.29; N, 4.73%.
1
(M+H+, PSP), [h]D23=+7.5 (c 0.8, CH2Cl2). H NMR: l
(ppm) 4.0–5.0 (9H, m, -OCH2-, H-2, H-3, H-4), 5.6
(3H, m, H-5, H-6a,b), 6.7 (1H, m, H-1), 6.8 and 7.5
(19H, m, aromatic). Cycloaddition starting from 20